Compare FBIZ & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBIZ | PRTA |
|---|---|---|
| Founded | 1909 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.9M | 539.9M |
| IPO Year | 2012 | 2013 |
| Metric | FBIZ | PRTA |
|---|---|---|
| Price | $55.74 | $10.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $65.00 | $19.00 |
| AVG Volume (30 Days) | 40.3K | ★ 419.1K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 14.23 | N/A |
| EPS | ★ 5.94 | N/A |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | $15.69 | $1,111.38 |
| Revenue Next Year | $8.47 | N/A |
| P/E Ratio | $9.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $45.90 | $4.32 |
| 52 Week High | $60.54 | $11.69 |
| Indicator | FBIZ | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 60.60 |
| Support Level | $53.56 | $9.69 |
| Resistance Level | $59.76 | $10.90 |
| Average True Range (ATR) | 1.36 | 0.35 |
| MACD | -0.20 | -0.00 |
| Stochastic Oscillator | 20.26 | 70.47 |
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products, including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically, all the business activity functioned through the region of the United States.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.